This study complies with all relevant ethical regulations and the bacterial strains and plasmids used in this study are listed in Table
S2. Unless otherwise noted,
S. aureus strains were grown in tryptic soy broth (TSB, Difco) at 37 °C with shaking (250 rpm), or on tryptic soy agar (TSA, Difco) at 37 °C.
Escherichia coli strains were grown in Luria-Bertani (LB) broth at 37 °C with shaking (250 rpm) or on LB agar plates at 37 °C. For plasmid maintenance, antibiotics were used at the following concentrations where appropriate: for
S. aureus,
erythromycin (Sangon Biotech) at 10 μg/ml for RN4220 and 80 μg/ml for USA300 LAC and its derivatives,
chloramphenicol (Sangon Biotech) at 15 μg/ml; for
E. coli,
carbenicillin (Sangon Biotech) at 150 μg/ml. For other reagents, tunicamycin and vancomycin (Dalian Meilun Biotech Co., Ltd.), targocil (Shanghai TopScience Co, Ltd.), oxacillin (Shanghai Aladdin Biochemical Technology Co.,Ltd.),
imipenem, cefuroxime, ceftizoxime, cefaclor, cefoxitin, and epicatechin gallate from MedChemExpress,
cefotaxime,
isopropyl β-D-1-thiogalactopyranoside (IPTG), and AIP from Sangon Biotech, anhydrotetracycline (aTc) from APExBIO, Tarocin A1 from Merck, moenomycin complex from GlpBio, and nile red from Yeasen Biotechnology Co., Ltd. were used in this study.
Lu Y., Chen F., Zhao Q., Cao Q., Chen R., Pan H., Wang Y., Huang H., Huang R., Liu Q., Li M., Bae T., Liang H, & Lan L. (2023). Modulation of MRSA virulence gene expression by the wall teichoic acid enzyme TarO. Nature Communications, 14, 1594.